IP Library Granted Patent US 10,912,767
Granted Patent B2
US 10,912,767 · App. 15/564,773 · Granted Feb 9, 2021

Anthracycline prodrugs and methods of making and using the same

Inventors: Tad H. Koch (Boulder, CO); Benjamin L. Barthel (Broomfield, CO); Hang Hubert Yin (Boulder, CO); Ryo Tamura (Boulder, CO); Alla Balabanova (Centennial, CO)
Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
A61K31/424A61K31/337A61K31/475A61K31/573A61K31/675A61K31/704A61K31/7056A61K45/06A61P35/00A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,912,767
App. No.
15/564,773
Granted
Feb 9, 2021
Kind
B2
Abstract

The present invention includes compounds of the class anthracycline that have been modified to include photo-activated prodrug anthracycline compounds that are useful in the treatment of cancer. One example composition of the invention may include photodoxazolidine which may be synthesized in two steps from 4,5-dimethoxy-2-nitrobenzyl alcohol and doxazolidine. In this embodiment commercial 4,5-dimethoxyl-2-nitrobenzyl alcohol reacts with p-nitrophenylchloroformate to give the p-nitrophenyl carbonate of the benzyl alcohol derivative. The p-nitrophenyl carbonate is then reacted with doxazolidine to give the exemplary photodoxazolidine composition.

Claims (7)

1. A compound having a chemical structure selected from the group consisting of:

and pharmaceutically-acceptable salts thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , and at least one excipient.

3. The pharmaceutical composition of claim 2 , further comprising wherein the composition is formulated for parenteral administration.

4. The pharmaceutical composition of claim 2 , further comprising wherein the composition is formulated for oral administration.

5. A method of treating cancer, comprising the step of administering an effective amount of at least one compound of claim 1 to a subject in need thereof and further photo-activating said at least one compound of claim 1 wherein the cancer is selected from the group consisting of ovarian cancer and breast cancer.

6. The method of claim 5 , wherein the at least one compound of claim 1 is co-administered with at least one of the following: 18-F-deoxyglucose (18-FDG), UV light, a PET scan, and Cherenkov radiation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2018
From: KOCH, TAD H.; TAMURA, RYO; BALABANOVA, ALLA; BARTHEL, BENJAMIN L.; YIN, HANG HUBERT
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 045258/0118 →
CONFIRMATORY LICENSE Recorded Feb 21, 2018
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044986/0516 →
Continuity (2)
Provisional Application 62153320 · Apr 27, 2015
Related Publication 20180110756A1 · Apr 26, 2018